Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Therapeutic or Preventive Procedure > Embolization, Therapeutic

Embolization, Therapeutic

Embolization, Therapeutic is a medical procedure involving the intentional blockage of blood vessels to stop or prevent bleeding, control blood flow, or destroy abnormal tissue.
This technique is used to treat a variety of conditions, including arteriovenous malformations, tumors, and hemorrhages.
The process involves the injection of small particles, such as coils or beads, into the targeted blood vessel to obstruct the flow of blood.
Embolization, Therapeutic is a minimally invasive procedure that can offer an effective alternative to more invasive surgical options in many cases.
Experince the future of protocol optimization today with PubCompare.ai.

Most cited protocols related to «Embolization, Therapeutic»

1
Doxorubicin for Unresectable Hepatocellular Carcinoma
Cited 21 times
Patients aged >18 years with HCC unsuitable for resection or percutaneous ablation, (BCLC A/B, without portal invasion or extrahepatic spread) were eligible for the study. Eligibility criteria also included: no previous chemotherapy, radiotherapy or transarterial embolization (with or without chemotherapy), a confirmed diagnosis of HCC according to EASL, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and preserved liver function (Child-Pugh Class A or B). Patients were excluded if they had another primary tumor, advanced liver disease (bilirubin levels >3 mg/dl, AST or ALT >5 × upper limit of normal or >250 U/l), advanced tumoral disease (vascular invasion or extrahepatic spread, or diffuse HCC, defined as >50% liver involvement), or contraindications for doxorubicin administration.
All patients provided written informed consent. The study was performed in accordance with the Declaration of Helsinki, the International Conference on Harmonization Guideline on Good Clinical Practice, and relevant local laws and regulations. Ethics committee approval was obtained. Independent Data and Safety Monitoring Committees were established to monitor efficacy and safety data. The study was registered at www.clinicaltrials.gov (NCT00261378), conducted according to the HCC Clinical Trial Design guidelines [27 (link)], and reported according to CONSORT recommendations [28 (link), 29 (link)].
Lammer J., Malagari K., Vogl T., Pilleul F., Denys A., Watkinson A., Pitton M., Sergent G., Pfammatter T., Terraz S., Benhamou Y., Avajon Y., Gruenberger T., Pomoni M., Langenberger H., Schuchmann M., Dumortier J., Mueller C., Chevallier P, & Lencioni R. (2009). Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study. Cardiovascular and Interventional Radiology, 33(1), 41-52.
Publication 2009
Bilirubin Blood Vessel Child Clinical Trials Data Monitoring Committees Conferences Diagnosis Doxorubicin Eligibility Determination Embolization, Therapeutic Ethics Committees Liver Liver Diseases Neoplasms Patients Pharmacotherapy Radiotherapy Safety
2
Hepatic Artery Infusion Chemotherapy and Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma
Cited 6 times
TACE was performed according to our previously reported protocol [16 (link)]. Chemolipiodolization was performed using 50 mg of epirubicin (pharmorubicin; Pfizer, Wuxi, Jiangsu, China), 50 mg of lobaplatin (Hainan Changan International Pharmaceutical Co. Ltd., Haikou, Hainan, China), and 6 mg of mitomycin C (Zhejiang Hisun Pharmaceutical Co. Ltd., Taizhou, Zhejiang, China) mixed with 10 mL of lipiodol (Lipiodol Ultra-Fluide; Guerbet Laboratories, Aulnay Sous Bois, Paris, France). If necessary, up to 20 mL of additional pure lipiodol was injected. The injection was stopped when stasis of blood flow in the target artery was observed. Subsequently, embolization was performed with the injection of polyvinyl alcohol particles that were 300–500 μm in diameter through the catheter to reach stasis in the tumor-feeding artery. Repeated TACE was performed at intervals of 6 weeks.
In the HAIC group, patients were treated using a 3-week cycle regimen. A catheter was advanced into the hepatic artery according to our previously reported protocol [16 (link)]. A microcatheter was selectively placed into the feeding arteries of the tumor. The gastroduodenal artery was occluded by a coil when necessary. Then, the microcatheter was connected to the artery infusion pump to administer the following treatment: OXA, 85 mg/m2 intra-arterial infusion on day 1; LV, 400 mg/m2 intra-arterial infusion on day 1; and 5-FU, 400 mg/m2 bolus infusion on day 1 and 2400 mg/m2 continuous infusion over 46 h. After HAIC was completed, the indwelling catheter and the sheath were removed, and manual compression was performed to achieve hemostasis.
HAIC and TACE were discontinued when disease progression (including vascular invasion or the development of extrahepatic spread) or intolerable AEs occurred or when the patient was eligible for another treatment (surgical resection) or withdrew consent. Additionally, the study treatment was suspended when the following conditions occurred: technical difficulty in repeating the treatment (stenosis or occlusion of the tumor-feeding artery or an artery only supplied by the extrahepatic collateral arteries) or unsuitable characteristics (neutrophil count < 1200/μL, platelet count < 60,000/μL, total bilirubin > 30 mmol/L, or albumin < 3.0 mg/dL). The study treatment was stopped if no recovery occurred after a 30-day delay.
If the study treatment was discontinued, the following treatment was defined as subsequent treatment. The subsequent treatment decisions of both groups would be made according to the same protocol by the same multidisciplinary team, based on the tumor burden, liver function, and the patient’s request. Basically, hepatic resections were performed on patients whose tumor shrank to be resectable. For patients with tumor progression without contraindications to TACE, repeating TACE was recommended. For patients whose residual tumors could not be embolized due to technical problems, radiofrequency ablations were used to destroy residual tumors when it was feasible. Conservative treatments were given to patients with terminal HCC, Child–Pugh C liver function, or Eastern Cooperative Oncology Group (ECOG) score > 2 [32 (link)].
He M.K., Le Y., Li Q.J., Yu Z.S., Li S.H., Wei W., Guo R.P, & Shi M. (2017). Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study. Chinese Journal of Cancer, 36, 83.
Full text: Click here
Publication 2017
ADAM17 protein, human Albumins Arterial Occlusion Arteries Bilirubin Blood Circulation Blood Vessel Catheters Child Conservative Treatment Disease Progression Embolization, Therapeutic Epirubicin Farmorubicin Hemostasis Hepatic Artery Indwelling Catheter Infusion Pump Intra-Arterial Infusions Lipiodol Liver lobaplatin MG 46 Mitomycin Neoplasms Neutrophil Operative Surgical Procedures Patients Pharmaceutical Preparations Platelet Counts, Blood Polyvinyl Alcohol Radiofrequency Ablation Residual Tumor Stenosis Treatment Protocols Tumor Burden
3
Postpartum Hemorrhage Measurement Protocol
Cited 6 times
The primary outcome of the trial was the incidence of postpartum haemorrhage, defined by a blood loss of ≥500 mL, measured with a graduated collector bag.25 (link) The main secondary outcomes were other objective measures of postpartum bleeding: measured blood loss ≥1000 mL at bag removal, mean measured blood loss at 15 minutes after birth (the bag had to be left in place at least 15 minutes to have one measure of blood loss at the same time point in all women), mean measured postpartum blood loss at bag removal, and mean changes in peripartum haemoglobin level and haematocrit (difference between haemoglobin level and haematocrit before delivery and at day 2 postpartum). Other secondary outcomes included use of supplementary uterotonic treatment; postpartum transfusion (until discharge); arterial embolisation or emergency surgery for postpartum haemorrhage; other characteristics of the third stage, including duration, manual removal of the placenta; and women’s experience of the third stage, assessed by a self administered questionnaire on day 2 postpartum. Safety outcomes included uterine inversion, cord rupture, and pain.
The detail of procedures used to manage the third stage, as well as all clinical outcomes identified during the immediate postpartum period, were prospectively collected by the midwife or obstetrician in charge of the delivery and recorded in the woman’s electronic form in the labour room. Other data were collected by a research assistant, independent of the local medical team. An independent data monitoring committee, which met monthly, was responsible for reviewing adherence to the trial procedures, recruitment, and safety data; the quality of collected outcome data was checked in each centre for 10% of the included women, randomly selected, and in all cases of postpartum haemorrhage.
Deneux-Tharaux C., Sentilhes L., Maillard F., Closset E., Vardon D., Lepercq J, & Goffinet F. (2013). Effect of routine controlled cord traction as part of the active management of the third stage of labour on postpartum haemorrhage: multicentre randomised controlled trial (TRACOR). The BMJ, 346, f1541.
Publication 2013
Arteries Blood Transfusion Childbirth Cone-Rod Dystrophy 2 Embolization, Therapeutic Emergencies Hemoglobin Hemorrhage Midwife Obstetric Delivery Obstetrician Operative Surgical Procedures Pain Patient Discharge Placenta Postpartum Hemorrhage Safety Uterine Inversion Volumes, Packed Erythrocyte Woman
4
Preoperative Liver Volumetry for PVE
Cited 6 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2012
Body Surface Area Embolization, Therapeutic Fibrosis Hepatectomy Injuries Light Liver Microspheres Multidetector Computed Tomography Patients Radionuclide Imaging Tromethamine X-Ray Computed Tomography
5
Acute Pulmonary Hypertension in Beagles
Cited 6 times
Acute PAH was induced by microbead injection in six female beagles (8.3 ± 2.4 kg body weight). The sequence of experimental procedures is outlined in Fig. 1.
General anesthesia was induced in all dogs by intraveneous propofol injection (10 mg/kg body weight). After endotracheal intubation, anesthesia was maintained with isoflurane (1–3%) in 100% oxygen using mechanical ventilation at a respiratory frequency of 11 breaths/min. Lactated Ringer’s solution was infused at a rate of 10 mL/kg/h. A femoral arterial catheter was inserted and systemic arterial pressure (SAP) and arterial blood gases were monitored. The femoral and external jugular veins were catheterized for RHC access, delivery of emboli, delivery of contrast for angiography and blood sampling. Thirty minutes after the stabilization of the animals, baseline CO, SAP, PAP (systolic, diastolic, mean), pulmonary capillary wedge pressure (PCWP), RV pressure, and right atrial pressure were measured.
While maintaining the dog under anesthesia, magnetic resonance imaging (MRI) and right heart catheterization (RHC) were repeated twice, first to obtain baseline vitals, pressures, RV function, and large PA geometry in the healthy animal (PRE tests), and second to measure the same parameters after acute PAH was successfully induced by embolization (POST tests). Dogs were humanely euthanized after the POST tests. All the procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Wisconsin-Madison.
Bellofiore A., Roldán-Alzate A., Besse M., Kellihan H.B., Consigny D.W., Francois C.J, & Chesler N.C. (2012). Impact of Acute Pulmonary Embolization on Arterial Stiffening and Right Ventricular Function in Dogs. Annals of biomedical engineering, 41(1), 195-204.
Publication 2012
Anesthesia Angiography Animals Arteries Atrium, Right Blood Gas Analysis Body Weight Canis familiaris Catheterizations, Cardiac Catheters Diastole Embolization, Therapeutic Females Femur General Anesthesia Institutional Animal Care and Use Committees Intubation, Intratracheal Isoflurane Jugular Vein Lactated Ringer's Solution Mechanical Ventilation Microspheres Obstetric Delivery Oxygen Propofol Pulmonary Wedge Pressure Respiratory Rate Systole

Most recents protocols related to «Embolization, Therapeutic»

1
Combination Therapy for Unresectable HCC
Not available on PMC !

Example 10

A patient with unresectable hepatocellular carcinoma is under treatment with sorafenib. The patient is receiving 400 mg per day of oral sorafenib (2×200 mg). In a single setting the patient is also treated with TheraSphere which consists of insoluble glass microspheres where yttrium-90 is bound within the spheres. The hepatic artery is catheterized and the tumor vascular bed is embolized with TheraSpehere delivering a target dose of TheraSphere of 100 Gy by injection through the hepatic artery. A dose of 0.1 cc per kg of DDFPe is mixed with oxygen and is also infused into the hepatic artery during the embolization procedure.

US11857627B2. Fractionated radiotherapy and chemotherapy with an oxygen therapeutic (2024-01-02). NuvOx Pharma LLC [US]. Inventors: Evan C. Unger [US].
Full text: Click here
Patent 2024
Blood Vessel Tumors Embolization, Therapeutic Hepatic Artery Hepatocellular Carcinomas Microspheres Oxygen Patients Pharmacotherapy Radiotherapy Sorafenib Yttrium-90
2
Comprehensive Cancer Patient Data Collection
Medical data collected for each patient in order to correlate biological data (including PDTO response to treatment) with clinical response are indicated in Table 2.

Medical data collected for each patient

Clinical parameters

Age, sex, weight, height, ECOG performance status,

Exposure to tobacco and alcohol,

Cancer location and TNM-8 classification

Histological diagnosisType, squamous differentiation, keratinization type, p16 status
Biologic parametersSerum neutrophils, albumin and leukocytes levels
Pathological pronostic factorsSurgical margin, lymph node metastasis with or without capsular rupture, vascular or lymphatic embolization, perineural invasion
Oncologic treatments

Radiotherapy (volume, dose, fraction)

Chemotherapy (molecules, administration regimen)

Response to treatment

Disease-free survival,

Progression-free survival,

Overall survival.

Perréard M., Florent R., Divoux J., Grellard J.M., Lequesne J., Briand M., Clarisse B., Rousseau N., Lebreton E., Dubois B., Harter V., Lasne-Cardon A., Drouet J., Johnson A., Le Page A.L., Bazille C., Jeanne C., Figeac M., Goardon N., Vaur D., Micault E., Humbert M., Thariat J., Babin E., Poulain L., Weiswald L.B, & Bastit V. (2023). ORGAVADS: establishment of tumor organoids from head and neck squamous cell carcinoma to assess their response to innovative therapies. BMC Cancer, 23, 223.
Full text: Click here
Publication 2023
Albumins Biopharmaceuticals Blood Vessel Capsule Electrocorticography Embolization, Therapeutic Ethanol Leukocytes Lymph Node Metastasis Malignant Neoplasms Neutrophil Patients Pharmacotherapy Tobacco Products Treatment Protocols
3
Surgical Approaches for Cardiac Myxoma Resection
In 25 patients (25/28, 89.29%), RHMs were excised through median sternotomy under cardiopulmonary bypass using aortic and bicaval cannulation (cardiac arrest in 23, beating heart in 2). To prevent detachment of the mass and intra-operative embolization, we minimized movement and compression of the heart during the surgery. Right atriotomy was performed in all 25 patients; of these, 2 cases were RVM, and ventricular tumors were approached across the tricuspid valve in 1 patient and through an extra right ventriculotomy in the other patient. The basic principle of excision was the complete resection of the tumor and its attached sites. The attachment sites of RHM are listed in Table 1. All myxomas were excised completely. The defect of the atrial septum and right atrial free wall after myxoma resection was repaired with a bovine or autologous pericardial patch when needed. Transesophageal echocardiography was performed at the end of the procedure to assess the presence of a residual tumor or interatrial shunting after septal reconstruction.
Of the remaining 3 patients, 2 underwent total endoscopic robotic RAM resection with da Vinci Surgical System (Intuitive Surgical, Sunnyvale, Calif, USA), and 1 underwent total thoracoscopic surgery for RAM resection. Both robotic and thoracoscopic surgeries are minimally invasive procedures for which the peripheral cardiopulmonary bypass was established via right internal jugular venous cannulation and femoral arterial and venous cannulations. In both these procedures, RAM was excised via right atriotomy on the beating heart without aortic occlusion. The principles for myxoma resection were the same as those for conventional surgeries with median sternotomy.
Liu Y., Li X., Liu Z., Jiang Y., Lu C., Ge S, & Zhang C. (2023). Clinical Characteristics and Surgical Outcomes of Right Heart Myxoma and Its Comparison with Left Heart Myxoma: A Single-Center Retrospective Study. Anatolian Journal of Cardiology, 27(3), 146-152.
Publication 2023
Aorta Arteries Atrial Septal Defects Atrium, Right Cannulation Cardiac Arrest Cardiac Tamponade Cardiopulmonary Bypass Cattle Dental Occlusion Echocardiography, Transesophageal Embolization, Therapeutic Endoscopy Femur Heart Heart Ventricle Jugular Vein Median Sternotomy Movement Myxoma Neoplasms Operative Surgical Procedures Patients Pericardium Reconstructive Surgical Procedures Residual Tumor Robotic Surgical Procedures Septum, Atrial Surgical Endoscopy Surgical Procedures, Thoracoscopic Valves, Tricuspid Veins
4
Retrospective Study of Unruptured VADA
A total of 16 patients with unruptured intracranial VADA from January 2017 to May 2021 in our institution were retrospectively included and reviewed. Digital subtractive angiography (DSA), magnetic resonance (MR), and computerized tomography (CT) angiography are usually used to aid in the diagnosis of VADA. The electronic medical record system provided the data on the patients. The Institutional Review Board of Yunnan First People's Hospital approved this study. Patients' therapeutic decisions (FD, stent-assisted coil embolization, or surgical clipping) were made after considering treatment risks, benefits, and the condition of patients. Patient informed consent is required from every patient before the procedure.
Lu X., Zhang Y., Zhou H., Jian L., Yin S., Li T, & Huang W. (2023). Flow diverters in the treatment of unruptured vertebral artery dissecting aneurysm: A single-center experience. Frontiers in Neurology, 14, 1050619.
Full text: Click here
Publication 2023
Angiography, Digital Subtraction Computed Tomography Angiography Diagnosis Embolization, Therapeutic Ethics Committees, Research Magnetic Resonance Imaging Operative Surgical Procedures Patients Stents
5
Coil Embolization of Unruptured Cerebral Aneurysms
In this study, we reviewed 181 patients with 230 unruptured cerebral aneurysms who underwent initial coil embolization at a single institution between 2011 and 2021. We excluded 27 patients with occlusion of the mother vessel, 15 patients who underwent flow-diverter implantation, six patients with thrombosed aneurysms, and one patient who was lost during follow-up. We retrospectively analyzed the correlation between neck width, maximum aneurysm size, width, aneurysm volume, 1st VER, and final VER of the cerebral aneurysm and recanalization requiring retreatment. Aneurysm volume was measured using a partially automated three-dimensional workstation (Allura 3D-RA workstation, Philips Medical Systems) from the rotational angiography data. The volume of the coils was defined as π (P/2)2 times the coil length, where p is the diameter of the primary coil. Final and 1st VERs were calculated according to the following equations:
1st VER = (the first coil volume)/(the aneurysm volume) × 100 Final VER = (total volume of all inserted coils)/(aneurysm volume) × 100
Nogami K., Misaki K., Tsutsui T., Nambu I., Kamide T, & Nakada M. (2023). The first coil embolization ratio is the key factor for retreatment for unruptured cerebral aneurysms. Surgical Neurology International, 14, 53.
Publication 2023
Aneurysm Angiography Blood Vessel Cerebral Aneurysm Dental Occlusion Embolization, Therapeutic Mothers Neck Ovum Implantation Patients Retreatments Versed

Top products related to «Embolization, Therapeutic»

1
Lipiodol by Guerbet
Sourced in France, United States, Germany, Italy, Japan, China
Lipiodol is a radiopaque contrast agent used in diagnostic medical imaging procedures. It is a sterile, iodinated, ethyl ester of fatty acids derived from poppy seed oil. Lipiodol is used to improve the visibility of certain structures or organs during radiographic examinations.
2
Progreat by Terumo
Sourced in Japan, Belgium, United States
Progreat is a laboratory equipment product designed for general laboratory use. It serves as a versatile tool for various applications within the research and scientific community.
3
Pipeline embolization device by Medtronic
Sourced in United States
The Pipeline Embolization Device is a lab equipment product manufactured by Medtronic. It is designed to assist in the treatment of cerebral aneurysms. The device is a flexible, braided, cylindrical implant that is placed within the affected blood vessel to divert blood flow and promote the formation of a clot, effectively sealing off the aneurysm.
4
Pharmorubicin by Pfizer
Sourced in China, United States, France
Pharmorubicin is a laboratory equipment product manufactured by Pfizer. It is used for research and development purposes in the pharmaceutical industry.
5
Lipiodol ultra fluide by Guerbet
Sourced in France, China
Lipiodol Ultra-Fluide is a radiopaque contrast agent manufactured by Guerbet. It is a water-insoluble, iodinated, ethyl ester of fatty acids derived from poppy seed oil. Lipiodol Ultra-Fluide is used for various radiological procedures to enhance visualization of anatomical structures during imaging.
6
2.7 f microcatheter by Terumo
Sourced in Japan
The 2.7-F microcatheter is a small-diameter catheter designed for accessing and navigating narrow vascular structures. It features a low profile and high flexibility to facilitate precise delivery of diagnostic or therapeutic agents.
7
Lipiodol ultrafluido by Guerbet
Sourced in France
Lipiodol Ultrafluido is a radiopaque contrast medium used for diagnostic imaging procedures. It is an iodized oil with a low viscosity that allows for easy injection and distribution within the body. The core function of Lipiodol Ultrafluido is to enhance the visibility of target tissues or structures during radiographic examinations.
8
5 f catheter by Cook Medical
Sourced in United States, Japan
The 5-F catheter is a medical device designed for use in various diagnostic and therapeutic procedures. It is a flexible tube with a diameter of 5 French (F), which is approximately 1.67 millimeters. The catheter is intended to be inserted into blood vessels or other body cavities to facilitate the passage of tools or fluids.
9
Lipiodol ultra fluid by Guerbet
Sourced in France
Lipiodol Ultra Fluid is a diagnostic agent manufactured by Guerbet. It is an iodinated poppy seed oil that is used as a radiocontrast medium for various radiological procedures.
10
Gelpart by Nippon Kayaku
Sourced in Japan
Gelpart is a laboratory equipment used for gel chromatography analysis. It is designed to separate and purify molecules based on their size and molecular weight.

More about "Embolization, Therapeutic"

Embolization, Therapeutic is a minimally invasive medical procedure that involves intentionally blocking blood vessels to stop or prevent bleeding, control blood flow, or destroy abnormal tissue.
This technique, also known as arterial embolization or vascular embolization, is used to treat a variety of conditions, including arteriovenous malformations, tumors, and hemorrhages.
The embolization process typically involves the injection of small particles, such as coils, beads, or liquid agents like Lipiodol, Progreat, or Pharmorubicin, into the targeted blood vessel to obstruct the flow of blood.
This procedure can be performed using catheters, such as a 2.7-F microcatheter or a 5-F catheter, to precisely deliver the embolizing agents.
Embolization, Therapeutic offers a minimally invasive alternative to more invasive surgical options in many cases.
It is a highly effective technique that can provide a viable solution for conditions that were previously difficult to treat.
The use of Lipiodol Ultra-Fluide or Lipiodol Ultrafluido as the embolizing agent, for example, can help to precisely target and occlude the desired blood vessels.
The field of Embolization, Therapeutic continues to evolve, with advancements in technology, such as the Pipeline Embolization Device, which can be used to treat complex vascular abnormalities.
Researchers and medical professionals are constantly exploring new applications and refining techniques to improve patient outcomes and provide the most effective treatments.